Search

TREATgermany, a registry for patients with moderate to severe atopic dermatitis (AD), established an additional questionnaire in spring 2020 to investigate the effects of the coronavirus pandemic on the daily life of patients with AD.A questionnaire was used to analyze general information regarding a patient's experience of the coronavirus pandemic and, using the Inventory of Life-Changing Events, the resulting personal burden. To analyze possible associations between disease severity (EASI score, oSCORAD, IGA, PGA, POEM), quality of life (DLQI) and personal burden, t-tests, analyses of variance and correlations were evaluated, controlled for sex and age.58 % (n = 233) of the included 400 registry patients reported high burden scores caused by the coronavirus pandemic, regardless of an actual infection. Men showed significantly higher burden scores than women, and younger than older respondents (both P = 0.03). There were no differences in burden scores related to the physician's assessment of disease severity. However, patients with higher quality of life impairments and higher disease severity perceived the burden of the coronavirus pandemic as less severe (DLQI P = 0.019, PGA P = 0.044).Our data show that registry patients considered the coronavirus pandemic as a life-changing event and perceived the burden differently. This should be taken into account in the treatment of patients with moderate to severe AD as well as in further studies.

Introduction Psoriasis is a systemic inflammatory disease characterised by pruritic skin lesions that impair quality of life (QOL). Long-Term Documentation of the Utilization of Apremilast in Patients with Plaque Psoriasis under Routine Conditions (LAPIS-PSO; ClinicalTrials.gov: NCT02626793) was a 52-week, prospective, multicentre, observational cohort study conducted in real-world dermatology clinical settings in Germany. We evaluated physician- and patient-reported outcomes for QOL, effectiveness and tolerability in patients with moderate to severe psoriasis vulgaris in LAPIS-PSO. Methods The primary endpoint was the percentage of patients achieving Dermatology Life Quality Index (DLQI) score ≤ 5 or ≥ 5-point improvement from baseline in DLQI score at visit 2 (~ 4 months after baseline). Secondary endpoints included assessments of symptoms and disease severity. Tolerability was evaluated based on adverse events (AEs). A pre-defined subgroup analysis based on baseline Physician’s Global Assessment (PGA) score (2 or 3 versus 4) was performed. Data were examined descriptively through visit 5 (~ 13 months) using the last-observation-carried-forward (LOCF) approach and data as observed. Results In total, 257 patients were included for efficacy assessment. On LOCF analysis, most patients achieved the primary endpoint at visit 2 (66.5%); DLQI response was maintained at visit 5 (72.4%). Earlier treatment response was observed in patients with a PGA score of 2 or 3 versus 4 (visit 1 PASI ≤ 3: 20.5% versus 10.8%). Adverse events were consistent with the known safety profile of apremilast. Conclusions In routine clinical care in Germany, patients with moderate to severe plaque psoriasis benefited from apremilast treatment up to ~ 13 months, consistent with findings from clinical trials, with a good safety profile. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-021-00658-x.

Hintergrund: TREATgermany, ein Register für Patienten mit moderater bis schwerer atopischer Dermatitis (AD), etablierte im Frühjahr 2020 einen zusätzlichen Fragebogen, um Auswirkungen der Corona-Pandemie auf die Lebenssituation von Patienten mit AD zu untersuchen. Methodik: Anhand eines Fragebogens wurden allgemeine Informationen zum Erleben der Corona-Pandemie und, unter Anwendung des Inventars lebensverändernder Ereignisse, die resultierenden Belastungen der Patienten untersucht. Zur Analyse möglicher Assoziationen zwischen Erkrankungsschwere (EASI-Score, oSCORAD, IGA, PGA, POEM), Lebensqualität (DLQI) und persönlichen Belastungen wurden t-Tests, Varianzanalysen und Korrelationen kontrolliert nach Geschlecht und Alter genutzt. Ergebnisse: 58 % (N = 233) der einbezogenen 400 Registerpatienten berichteten eine hohe Belastung durch die Corona-Pandemie, unabhängig von einer tatsächlichen Infektion. Männer zeigten signifikant höhere Belastungswerte als Frauen sowie jüngere höhere als ältere Befragte (jeweils P = 0,03). Es gab keine Unterschiede der Belastungswerte bezogen auf die ärztliche Beurteilung der Erkrankungsschwere. Jedoch reflektierten Patienten mit höherer Einschränkung der Lebensqualität und ausgeprägterer Krankheitslast die Belastung durch die Corona-Pandemie als weniger hoch (DLQI P = 0,019, PGA P = 0,044). Schlussfolgerungen: Es konnte gezeigt werden, dass die Registerpatienten die Corona-Pandemie als lebensveränderndes Ereignis reflektieren und die Belastung unterschiedlich wahrnehmen. Dies sollte sowohl bei der Behandlung von Patienten mit moderater bis schwerer AD berücksichtigt als auch in weiterführenden Untersuchungen vertieft werden., BACKGROUND: TREATgermany, a registry for patients with moderate to severe atopic dermatitis (AD), established an additional questionnaire in spring 2020 to investigate the effects of the coronavirus pandemic on the daily life of patients with AD.; MATERIAL AND METHODS: A questionnaire was used to analyze general information regarding a patient's experience of the coronavirus pandemic and, using the Inventory of Life-Changing Events, the resulting personal burden. To analyze possible associations between disease severity (EASI score, oSCORAD, IGA, PGA, POEM), quality of life (DLQI) and personal burden, t-tests, analyses of variance and correlations were evaluated, controlled for sex and age.; RESULTS: 58% (n=233) of the included 400 registry patients reported high burden scores caused by the coronavirus pandemic, regardless of an actual infection. Men showed significantly higher burden scores than women, and younger than older respondents (both P=0.03). There were no differences in burden scores related to the physician's assessment of disease severity. However, patients with higher quality of life impairments and higher disease severity perceived the burden of the coronavirus pandemic as less severe (DLQI P=0.019, PGA P=0.044).; CONCLUSIONS: Our data show that registry patients considered the coronavirus pandemic as a life-changing event and perceived the burden differently. This should be taken into account in the treatment of patients with moderate to severe AD as well as in further studies. © 2021 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.